Uploaded August 2026 | Updated September 2026, 2 weeks ago
Dr. Prabodh Satyal presents "Chiral Analysis for Authentication of Cannabis" at CannMed 2026, covering chiral chromatography, terpene authentication, and cannabis adulteration.
Authenticating cannabis extracts and identifying adulteration have become critical to ensuring consumer safety and product efficacy. This study applies chiral gas chromatography (GC) to differentiate naturally derived cannabis terpenes from synthetic or plant-derived analogs, establishing chirality as a key marker of authenticity.
Chiral GCMS was used to analyze multiple cannabis samples for enantiomeric distribution of key terpenes and cannabinoids. The method focused on the major enantiomeric pairs: (+) and (-) alpha-pinene, camphene, beta-pinene, limonene, linalool, borneol, fenchol, trans-beta-caryophyllene, trans-nerolidol, and caryophyllene oxide. Comparative evaluation was conducted between authentic cannabis derived terpenes and synthetic or secondary source materials.
Authentic cannabis samples consistently showed distinct enantiomeric dominance patterns, such as (+) alpha-pinene (88-95%), (+) camphene (55-70%), (+) beta-pinene (83-87%), (-) limonene (83-93%), (+) linalool (67-95%), (-) borneol (62-84%), (+) fenchol (90-95%), (-) trans-beta-caryophyllene (100%), (+) trans-nerolidol (95-99%), and (-) caryophyllene oxide (90-99%). These results demonstrate that while chemical composition may vary slightly between batches or cultivars, the enantiomeric ratios remain consistent for a given species, making chirality a reliable authenticity marker.
Chiral analysis provides a robust scientific foundation for cannabis authentication. Terpene chirality serves as a fingerprint for natural origin and can expose adulteration with synthetic or non-cannabis derived components. Understanding and preserving enantiomeric integrity not only enhances quality assurance but also supports the Entourage Effect, ensuring that product efficacy and natural synergy are maintained.
Learning Objectives:
⦿ Learning the use of chiral chromatography
⦿ Terpene chirality is essential for the authentication of the source
⦿ Cannabinoid chirality plays essential roles in understanding biosynthetic pathways
Dr. Prabodh Satyal is a chemist and essential oil scientist recognized internationally as a leading authority in terpene research and adulteration analysis. With over two decades of experience, he has published more than 250 research papers and analyzed over 500,000 essential oils and terpenes from around the world. As Chief Scientific Officer of the Aromatic Plant Research Center (APRC), Dr. Satyal leads global research on authenticity, purity, and synthetic adulteration in natural products, including cannabinoids. His current focus is on cannabis chemotyping, chiral GC-MS profiling, and the identification of synthetic markers that reveal chemical modification and mislabeling in cannabis-derived products. His stereochemical and chemometric studies have shaped modern approaches to quality control and authenticity verification across the natural products industry.
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
Dr. Prabodh Satyal presents "Chiral Analysis for Authentication of Cannabis" at CannMed 2026, covering chiral chromatography, terpene authentication, and cannabis adulteration.
Authenticating cannabis extracts and identifying adulteration have become critical to ensuring consumer safety and product efficacy. This study applies chiral gas chromatography (GC) to differentiate naturally derived cannabis terpenes from synthetic or plant-derived analogs, establishing chirality as a key marker of authenticity.
Chiral GCMS was used to analyze multiple cannabis samples for enantiomeric distribution of key terpenes and cannabinoids. The method focused on the major enantiomeric pairs: (+) and (-) alpha-pinene, camphene, beta-pinene, limonene, linalool, borneol, fenchol, trans-beta-caryophyllene, trans-nerolidol, and caryophyllene oxide. Comparative evaluation was conducted between authentic cannabis derived terpenes and synthetic or secondary source materials.
Authentic cannabis samples consistently showed distinct enantiomeric dominance patterns, such as (+) alpha-pinene (88-95%), (+) camphene (55-70%), (+) beta-pinene (83-87%), (-) limonene (83-93%), (+) linalool (67-95%), (-) borneol (62-84%), (+) fenchol (90-95%), (-) trans-beta-caryophyllene (100%), (+) trans-nerolidol (95-99%), and (-) caryophyllene oxide (90-99%). These results demonstrate that while chemical composition may vary slightly between batches or cultivars, the enantiomeric ratios remain consistent for a given species, making chirality a reliable authenticity marker.
Chiral analysis provides a robust scientific foundation for cannabis authentication. Terpene chirality serves as a fingerprint for natural origin and can expose adulteration with synthetic or non-cannabis derived components. Understanding and preserving enantiomeric integrity not only enhances quality assurance but also supports the Entourage Effect, ensuring that product efficacy and natural synergy are maintained.
Learning Objectives:
⦿ Learning the use of chiral chromatography
⦿ Terpene chirality is essential for the authentication of the source
⦿ Cannabinoid chirality plays essential roles in understanding biosynthetic pathways
Dr. Prabodh Satyal is a chemist and essential oil scientist recognized internationally as a leading authority in terpene research and adulteration analysis. With over two decades of experience, he has published more than 250 research papers and analyzed over 500,000 essential oils and terpenes from around the world. As Chief Scientific Officer of the Aromatic Plant Research Center (APRC), Dr. Satyal leads global research on authenticity, purity, and synthetic adulteration in natural products, including cannabinoids. His current focus is on cannabis chemotyping, chiral GC-MS profiling, and the identification of synthetic markers that reveal chemical modification and mislabeling in cannabis-derived products. His stereochemical and chemometric studies have shaped modern approaches to quality control and authenticity verification across the natural products industry.
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.

![What were some improvements/outcomes from the sleep study of children with Autism Spectrum Disorder?
Dr. Mohsin Maqbool is a pediatric neurologist and sleep specialist based in Dallas–Fort Worth, Texas. His work focuses on the intersection of neurodevelopment, sleep, and cannabinoid therapeutics in autism spectrum disorder. He is particularly interested in how cannabinoid formulations may influence sleep regulation, behavior, and quality of life in children with autism.
At CannMed 26, Mohsin will present “Autism, Sleep, and Medicinal Cannabis: Evaluating 18-Month Efficacy and Safety Outcomes”
During our conversation, we discuss:
- The gaps in current sleep medicine for children with Autism Spectrum Disorder
- Results from Mohsin’s 18-month longitudinal study including improvements to total sleep time, sleep onset and maintenance, and overall quality of sleep
- The method of finding the effective dose for each patient
- Cannabinoids’ effect on the duration of REM sleep and what the daytime implications are
- Thinking of cannabis as a tool to supplement conventional ASD medications and not a replacement
- Future research directions - using wearables and EEG to investigate how cannabinoids affect sleep architecture and brain physiology, as well as using biomarkers to see whether patients are a good candidate for cannabinoid therapies
Thanks to This Episode’s Sponsor: The Society of Cannabis Clinicians
The Society of Cannabis Clinicians is a nonprofit professional association of physicians and other healthcare providers. It provides continuing education—for clinicians, patients, and all concerned about the medical use of cannabis and best practices in clinical care. SCC physicians have been monitoring cannabis use by patients for 20 years and have compiled a wealth of clinical evidence and treatment strategies that will be validated by clinical trials in the years ahead.
To learn more about SCC and to join visit cannabisclinicians.org.
Additional Resources
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study - https://pmc.ncbi.nlm.nih.gov/articles/PMC12563248/
- [Book] Cannabis Is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain by Dr. Bonni Goldstein - https://www.amazon.com/Cannabis-Medicine-Medical-Healing-Everything/dp/031650078X
- Register for CannMed 26 - https://cannmedevents.com/package-options/
- Meet the CannMed 26 Speakers - https://cannmedevents.com/speakers/
- Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
- CannMed Archive - https://cannmedevents.com/cannmed-video-archives/ What were some improvements/outcomes from the sleep study of children with Autism Spectrum Disorder?](https://i.ytimg.com/vi/vrI_ylBACeg/mqdefault.jpg)

![Improving Sleep for Children with Autism Spectrum Disorder - Mohsin Maqbool, MD
Dr. Mohsin Maqbool is a pediatric neurologist and sleep specialist based in Dallas–Fort Worth, Texas. His work focuses on the intersection of neurodevelopment, sleep, and cannabinoid therapeutics in autism spectrum disorder. He is particularly interested in how cannabinoid formulations may influence sleep regulation, behavior, and quality of life in children with autism.
At CannMed 26, Mohsin will present “Autism, Sleep, and Medicinal Cannabis: Evaluating 18-Month Efficacy and Safety Outcomes”
During our conversation, we discuss:
- The gaps in current sleep medicine for children with Autism Spectrum Disorder
- Results from Mohsin’s 18-month longitudinal study including improvements to total sleep time, sleep onset and maintenance, and overall quality of sleep
- The method of finding the effective dose for each patient
- Cannabinoids’ effect on the duration of REM sleep and what the daytime implications are
- Thinking of cannabis as a tool to supplement conventional ASD medications and not a replacement
- Future research directions - using wearables and EEG to investigate how cannabinoids affect sleep architecture and brain physiology, as well as using biomarkers to see whether patients are a good candidate for cannabinoid therapies
Thanks to This Episode’s Sponsor: The Society of Cannabis Clinicians
The Society of Cannabis Clinicians is a nonprofit professional association of physicians and other healthcare providers. It provides continuing education—for clinicians, patients, and all concerned about the medical use of cannabis and best practices in clinical care. SCC physicians have been monitoring cannabis use by patients for 20 years and have compiled a wealth of clinical evidence and treatment strategies that will be validated by clinical trials in the years ahead.
To learn more about SCC and to join visit cannabisclinicians.org.
Additional Resources
- Effects of Medical Cannabis Treatment for Autistic Children on Family Accommodation: An Open-Label Mixed-Methods Study - https://pmc.ncbi.nlm.nih.gov/articles/PMC12563248/
- [Book] Cannabis Is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain by Dr. Bonni Goldstein - https://www.amazon.com/Cannabis-Medicine-Medical-Healing-Everything/dp/031650078X
- Register for CannMed 26 - https://cannmedevents.com/package-options/
- Meet the CannMed 26 Speakers - https://cannmedevents.com/speakers/
- Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
- CannMed Archive - https://cannmedevents.com/cannmed-video-archives/ Improving Sleep for Children with Autism Spectrum Disorder - Mohsin Maqbool, MD](https://i.ytimg.com/vi/w1ZQaf1ZieY/mqdefault.jpg)






